Maartje C.A. Wouters

Author

University Medical Center Groningen ORCID

Also Known As

M. C. A. Wouters, M. Wouters, M.C.A. Wouters, MCA Wouters, Maartje C A Wouters, Maartje C. A. Wouters, Maartje C. Wouters, Maartje C.A. Wouters, Maartje CA Wouters, Maartje Wouters

124

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

University Medical Center Groningen University of Groningen University of British Columbia University of Victoria

About

Maartje C.A. Wouters is an author at University Medical Center Groningen specializing in immunology, medicine, and tumor microenvironment.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	490
2	Immunology	6	6	490
3	Cell Biology	3	3	131
4	Pathology	3	3	359
5	Autoimmunity	1	1	68

Maartje C.A. Wouters

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer Hagma H. Workel, Joyce M. Lubbers, Roland Arnold, Cancer Immunology Research	2019	249
Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers Eleni van Schooneveld, Maartje C.A. Wouters, Ilse Van der Auwera, Breast Cancer Research	2012	191
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer E. M. Dijkgraaf, Saskia J. Santegoets, A.K.L. Reyners, Annals of Oncology MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer Treatment	2015	189
CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma Hagma H. Workel, Fenne L. Komdeur, Maartje C.A. Wouters, European Journal of Cancer Endometrial AdenocarcinomaCancer ImmunosurveillanceOncologyMedicineImmunology	2016	137
Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer Céline M. Laumont, Maartje C.A. Wouters, Julian Smazynski, Clinical Cancer Research	2021	97
Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer Dale W. Garsed, Kathryn Alsop, Sián Fereday, Clinical Cancer Research	2017	91
Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer Maartje C.A. Wouters, Fenne L. Komdeur, Hagma H. Workel, Clinical Cancer Research	2015	80
CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy Fenne L. Komdeur, Maartje C.A. Wouters, Hagma H. Workel, Oncotarget Checkpoint InhibitionLymphocyte DevelopmentT-regulatory CellImmunologyImmune Regulation	2016	68
CD20<sup>+</sup>T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer Marco de Bruyn, Valerie R. Wiersma, Maartje C.A. Wouters, OncoImmunology	2015	35
Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer Allyson C. Banville, Maartje C.A. Wouters, Ann L. Oberg, Gynecologic Oncology Chimeric Antigen ReceptorCancer ImmunosurveillanceImmunologyRecurrent Ovarian CancerCell Target	2020	35

Page 1